SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of report: June 30, 2021
(Date of earliest event reported)
(Exact name of registrant as specified in its charter)
|(State or other jurisdiction||(Commission File Number)||(IRS Employer|
|of incorporation)||Identification No.)|
3100 Sanders Road, Suite 301
Northbrook, Illinois 60062
(Address of principal executive offices, including zip code)
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|☐||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|☐||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|☐||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|☐||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
|Title of Each Class||Trading Symbol(s)||Name of Each Exchange on Which Registered|
|Common Stock, par value $.01 per share||IEX||New York Stock Exchange|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
|Emerging growth company||☐|
|If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐|
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As previously reported, on June 17, 2021, Daniel J. Salliotte, Senior Vice President, Corporate Development of the Company, and the Company agreed to separate, and Mr. Salliotte is expected to remain with the Company until March 1, 2022 (the “Separation Date”). In connection with the separation, the Company and Mr. Salliotte entered into a severance and general release agreement, dated June 30, 2021 (the “Severance Agreement”), pursuant to which Mr. Salliotte will remain with the Company until the Separation Date and provide transition services.
Pursuant to the Severance Agreement, Mr. Salliotte will continue to be paid his current base salary and be entitled to the same medical benefits applicable to his employment until the Separation Date. Following the Separation Date, and subject to Mr. Salliotte’s compliance with the terms of the Severance Agreement, Mr. Salliotte will receive each of the following payable in a lump sum: $31,616 for medical continuation coverage in addition to the base salary and target bonus severance provided for under Mr. Salliotte’s employment offer letter with the Company, dated September 30, 2010, previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2012. The Severance Agreement includes a general release and waiver from Mr. Salliotte.
Item 9.01 – Financial Statements and Exhibits.
104 Cover Page Interactive Data File (the cover page XBRL tags embedded within the Inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|By:||/s/ WILLIAM K. GROGAN|
|William K. Grogan|
|Senior Vice President and Chief Financial Officer|
|July 2, 2021|
|104||Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)|